ATLANTA–(BUSINESS WIRE)–MyEyeDr., a leading provider of eye health services with over 850 locations across the U.S., teamed up with two-time WNBA All-Star and 2020 3×3 Basketball Gold Medalist, Allisha Gray to promote the importance of eye health in …
Author: Business Wire
National Vision Opens 2024-2025 Scholarship Program, Highlighting AI’s Role in the Future of Eye Care
DULUTH, Ga.–(BUSINESS WIRE)–National Vision, Inc., one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, announced today that its annual scholarship program is open for entries, offering eligible optometry …
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 20…
BeeKeeperAI and Topcon Healthcare Inc. Team Up to Accelerate Healthcare from the Eye™
SAN FRANCISCO & OAKLAND, N.J.–(BUSINESS WIRE)– #AI–BeeKeeperAI®, Inc., a pioneer in privacy-enhancing, multi-party collaboration software for artificial intelligence (AI) development and deployment, and Topcon Healthcare, Inc., a leading provider of…
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
FRIENDSWOOD, Texas–(BUSINESS WIRE)—- $CSTL #2024SMRCongress–Castle will present new data on DecisionDx-Melanoma and DecisionDx-UM at the 21st International Congress of the Society for Melanoma Research (SMR).
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third…
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative…
Global Quantum Sensors Market Report 2025-2035: Company Profiles of Airbus, Atomionics, Chipiron, ColdQuanta, EuQlid, Infleqtion, Mesa Quantum, MuQuans, NVision, Q-CTRL, Qnami, Quantum Systems & More – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Market for Quantum Sensors 2025-2035” report has been added to ResearchAndMarkets.com’s offering. Quantum sensing is an emerging technology that allows for extremely precise measurements at the atomic level. It offe…
Thermo Fisher Scientific Showcases Expanded Biopharma Services, Capabilities and Innovations at CPHI Milan 2024
MILAN–(BUSINESS WIRE)–Thermo Fisher Scientific Inc., the world leader in serving science, will showcase its latest innovations enabling the molecule-to-medicine journey and host a series of sessions that feature industry developments during CPHI Mila…
Transcend Vivoscope to Offer Turnkey Miniature Two-photon Imaging Systems with poLight ASA Tunable Optics
HORTEN, Norway–(BUSINESS WIRE)– #Alzheimers–Transcend Vivoscope will debut the SUPERNOVA-600 mini2P, incorporating poLight ASA TLens® tunable optics, at the #SfN’24 event Oct. 5-9 in Chicago, IL
Marshall B. Ketchum University Hosts Second Annual Alumni Homecoming and Distinguished Alumni Awards
FULLERTON, Calif.–(BUSINESS WIRE)– #AlumniAwards–Marshall B. Ketchum University (MBKU) recently recognized the remarkable accomplishments of its alumni during the 2024 Distinguished Alumni Awards Ceremony during its second annual homecoming event. T…
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the res…
Harrow Relaunches TRIESENCE®
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative‑free synthetic co…
Novaliq和Laboratoires Théa宣布建立合作伙伴关系并获得Vevizye®(环孢菌素0.1%滴眼液)欧盟批准
德国海德堡、马萨诸塞州坎布里奇和法国克莱蒙特-费朗–(BUSINESS WIRE)–(美国商业资讯)– 以独特的EyeSol®无水技术为基础、专注开发一流眼科治疗药物的生物制药公司Novaliq与欧洲领先的独立眼科护理集团Laboratoires Théa (Théa) 宣布，Vevizye®（环孢素0.1%滴眼液）获得欧盟委员会批准，并且双方已签订合作伙伴关系协议，Théa获得该产品在欧洲及中东和北非（MENA）部分国家的商业化权利。 Vevizye®以Novaliq的专利EyeSol®技术…
Samenvatting: Novaliq en Laboratoires Théa kondigen een partnerschap en EU-goedkeuring aan voor Vevizye® (oogdruppels met 0,1% ciclosporine)
HEIDELBERG, Duitsland & CAMBRIDGE, Mass. & CLERMONT-FERRAND, Frankrijk–(BUSINESS WIRE)–Novaliq, een biofarmaceutisch bedrijf dat zich toespitst op oogtherapeutica van topkwaliteit op basis van de unieke, watervrije EyeSol®-technologie, en Laboratoire…
Riassunto: Novaliq e Laboratoires Théa annunciano la sigla di una partnership e l’approvazione da parte della UE di Vevizye® (soluzione in collirio liquido allo 0,1% di ciclosporin)
HEIDELBERG, Germania & CAMBRIDGE, Mass. & CLERMONT-FERRAND, Francia–(BUSINESS WIRE)–Novaliq, una società biofarmaceutica il cui focus è sullo sviluppo di terapie oculari all’avanguardia basate sull’esclusiva tecnologia EyeSol® per prodotti privi di a…
Novaliq et les laboratoires Théa annoncent un partenariat et l'approbation par l'UE de Vevizye® (solution de collyre à 0,1 % de ciclosporine)
HEIDELBERG, Allemagne & CAMBRIDGE, Mass. & CLERMONT-FERRAND, France–(BUSINESS WIRE)–Novaliq, société biopharmaceutique spécialisée dans les traitements oculaires de première et de meilleure qualité basés sur la technologie unique sans eau EyeSol®, et…
Novaliq und Laboratoires Théa verkünden Partnerschaft und EU-Zulassung für Vevizye® (0,1%ige Ciclosporin-Augentropfenlösung)
HEIDELBERG, Deutschland & CAMBRIDGE, Mass. & CLERMONT-FERRAND, Frankreich–(BUSINESS WIRE)–Novaliq, ein biopharmazeutisches Unternehmen, das sich auf erste und beste Augentherapeutika konzentriert, die auf der einzigartigen wasserfreien EyeSol®-Techno…
Resumen: Novaliq y Laboratoires Théa anuncian su asociación y la aprobación en la UE de Vevizye® (ciclosporina 0,1 % solución colirio)
HEIDELBERG, Alemania y CAMBRIDGE, Massachusetts y CLERMONT-FERRAND, Francia–(BUSINESS WIRE)–Novaliq, una compañía biofarmacéutica centrada en la primera y mejor terapia ocular de su clase basada en la exclusiva tecnología EyeSol® sin agua, y Laborato…
Morphotonics Appoints Hugo da Silva as New CEO to Lead Company Into Next Phase of Growth
VELDHOVEN, Netherlands–(BUSINESS WIRE)–Morphotonics, a global leader in large-area nanoimprint technology, is proud to announce the appointment of Hugo da Silva as its new Chief Executive Officer (CEO). With over 20 years of experience in advanced ma…